[1]He J, Huang Z, Han L, et al. Mechanisms and management of 3rdgeneration EGFRTKI resistance in advanced nonsmall cell lung cancer[J]. International journal of oncology, 2021, 59(5): 1-20. *本材料由阿斯利康提供,仅供医疗...
近日,同济大学附属上海市肺科医院苏春霞教授团队在《Biol Proced Online》上发表了题为“Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance”的一项研究...
在晚期表皮生长因子受体(EGFR)敏感突变(Ex19del/L858R)非小细胞肺癌(NSCLC)领域,多项大型III期临床研究[1-4]已证实,三代EGFR酪氨酸激酶抑制剂(EGFR-TKI)较一代EGFR-TKI可显著提升患者获益。但即使三代EGFR-TKI治疗效果显著,患者仍要...
此外还有研究显示,在abivertinib耐药的患者中也检测到AXL扩增。因此,AXL激活和AXL扩增可能是导致第三代EGFR-TKI原发和继发耐药的机制之一。 全文完。 参考文献: [1] He J, Huang Z, Han L, et al. Mechanisms and management of 3rd-generation...
本文主要参考Chen Q, Xia L, Wang J, et al. EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment. Lung Cancer. Published online May 10, 2024. doi:10.1016/j.lungcan.2024.107815。
Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.第三代EGFR-TKI耐药性机制及联合用药治疗的策略。西南证券、国信证券、贝达药业、强生公司官网等网上公开资料。当医疗器械行业进入开放、共享、精准的数字化营销时代，以往...
Bosch-Barrera J, Sala MÁ, Sereno M, Romero A, Provencio M. Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation. Cancers (Basel). 2022 Sep 13;14(18):4446. doi: 10.3390/cancers14184446. PMID: 36139605; PMCID: PMC...
Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib. Anticancer Drugs. 2024 Jan 1;35(1):93-96. doi: 10.1097/CAD.0000000000001530. Epub 2023 Jul 7. PMID: 37449979....
总体来说,脱靶耐药(Off-target resistance)的比例高于靶点依赖性耐药(On-target resistance)。 三代EGFR TKI耐药后的进展模式主要分为寡进展、颅内进展、多发进展。对于寡进展和颅内进展后可继续第三代 EGFR - TKI 治疗联合局部治疗;而...
图-1:伴有EGFR突变和软脑膜转移(LM)的NSCLCEGFR-TKI:EGFR酪氨酸激酶抑制剂 相较于传统的化疗药物,EGFR-TKI更容易穿透血脑屏障[9]。第一代EGFR-TKI,如吉非替尼和厄洛替尼,在NSCLC患者脑脊液中的浓度和渗透率相对有限,平均脑脊液浓度分别为...